Clinical manifestations of herpes simplex virus infection in children with atopic dermatitis
https://doi.org/10.21508/1027-4065-2018-63-6-15-22
Abstract
Atopic dermatitis is a disease of early childhood. Most children are infected with the herpes simplex virus at this age. The changes in the congenital and adaptive immunity in children with atopic dermatitis create precondition for the development of infectious complications, including those caused by herpes viruses. The authors of the article discuss details of various clinical manifestations of herpes infection in children with atopic dermatitis and they carry out differential diagnostics. Particular attention is paid to herpes eczema – the severe complication of atopic dermatitis in the course of disseminated herpes infection.
Conflict of interest: The authors of this article confirmed the lack of conflict of interest and financial support, which should be reported.
About the Authors
O. B. Tamrazova
People’s Friendship University of Russia of the Ministry of Education and Science;
Bashlyaeva Children’s City Clinical Hospital
Russian Federation
Russian Federation
T. A. Chebotareva
Russian Medical Academy of Post-Graduate Professional Education
Russian Federation
Russian Federation
A. S. Stadnikova
Bashlyaeva Children’s City Clinical Hospital
Russian Federation
Russian Federation
A. V. Taganov
People’s Friendship University of Russia of the Ministry of Education and Science
Russian Federation
Russian Federation
References
1. Федеральные клинические рекомендации по ведению больных с атопическим дерматитом. М 2015; 40. [Federal clinical guidelines for management of patients with atopic dermatitis. Moscow 2015; 40. (in Russ)]
2. Leung D.Y., Bieber T. Atopic dermatitis. Lancet 2003; 361: 151–160.
3. Silverberg J.I., Hanifin J.M. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol 2013; 132(5): 1132–1138. DOI:10.1016/j. jaci.2013.08.031
4. Lee J.H, Son S.W, Cho S.H. A comprehensive review of the treatment of atopic eczema. Allergy Asthma Immunol Res 2016; 8(3): 181–190. DOI: 10.4168/aair.2016.8.3.181
5. Garmhausen D., Hagemann T., Bieber T., Dimitriou I., Fimmers R., Diepgen T., Novak N. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy 2013; 68(4): 498–506. DOI:10.1111/all.12112
6. Weidinger S., Novak N. Atopic dermatitis. Lancet Lond Engl 2016; 387(10023): 1109–1122. DOI: 10.1016/S0140- 6736(15)00149-X
7. Koelle D.M., Norberg P., Fitzgibbon M.P., Russell R.M., Greninger A.L., Huang M.L. et al. Worldwide circulation of HSV2×HSV-1 recombinant strains. Sci Rep 2017; 7: 44084. DOI: 10.1038/srep44084
8. Kolb A.W., Larsen I.V., Cuellar J.A., Brandt C.R. Genomic, phylogenetic, and recombinational characterization of herpes simplex virus 2 strains. J Virol 2015; 8(4): 6427–6434. DOI: 10.3390/v80401
9. Pebody R.G., Andrews N., Brown D., Gopal R., de Melker H., Francois G., Gatcheva N. et al. The seroepidemiology of herpes simplex virus type 1 and 2 in Europe. Sexually Transmitted Infections 2004; 80: 185-191. DOI: 10.1136/sti.2003.005850
10. Wald A., Corey L. Persistence in the population: epidemiology, transmission. In: Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge Cambridge University Press, 2007; 14.
11. Kolokotronis A., Doumas S. Herpes simplex virus infection, with particular reference to the progression and complications of primary herpetic gingivostomatitis. Clin Microbiol Infect 2006; 12(3): 202–211. DOI: 10.1111/j.1469- 0691.2005.01336.x
12. Wollenberg A., Bieber T. Atopic dermatitis: from the genes to skin lesions. Allergy 2000; 55: 205–213.
13. Zaniboni M.C., Samorano L.P., Orfali R.L., Aoki V. Skin barrier in atopic dermatitis: beyond filaggrin. An Bras Dermatol 2016; 91(4): 472–478. DOI: 10.1590/abd1806- 4841.20164412
14. Wong W.J, Richardson T., Seykora J.T., Cotsarelis G., Simon M.C. Hypoxia-inducible factors regulate filaggrin expression and epidermal barrier function. J Invest Dermatol 2015; 135(2): 454–461. DOI: 10.1038/jid.2014.283
15. Vavrova K., Henkes D., Struver K., Sochorova M., Skolova B., Witting M.Y. et al. Filaggrin deficiency leads to impaired lipid profile and altered acidification pathways in a 3D skin construct. J Invest Dermatol 2014; 134: 746–753. DOI: 10.1038/ jid.2013.402
16. Thyssen J.P., Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 2014; 134(3): 792–799. DOI: 10.1038/ jid.2013.402
17. Gao P.S., Rafaels N.M., Hand T., Murray T., Boguniewicz M., Hata T. et al. Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum. J Allergy Clin Immunol 2009; 124(3): 507–513. DOI: 10.1016/j. jaci.2009.07.034
18. Valdes-Rodriguez R., Saavedra-Alanis V.M., Islas-Aguilar M.A., Torres-Alvarez B. Eczema herpeticum in a patient with atopic dermatitis, carrying r501x and 2282del4 filaggrin null mutations. Gac Med Mex 2015; 151(2): 252–255.
19. O’Neill C.A, Garrod D. Tight junction proteins and the epidermis. Exp Dermatol 2011; 20(2): 88–91. DOI: 10.1111/j.1600-0625.2010.01206.x
20. Niessen C.M. Tight junctions/adherens junctions: basic structure and function. J Invest Dermatol 2007; 127(11): 2525– 2532. DOI: 10.1038/sj.jid.5700865
21. Wollenberg A., Zoch C., Wetzel S., Plewig G., Przybilla B. Predisposing factors and clinical features of eczema herpeticum–a retrospective analysis of 100 cases. J Am Acad Dermatol 2003; 49(2): 198–205.
22. Engler R.J.M., Kenner J., Leung D.Y. Smallpox vaccination: risk considerations for patients with atopic dermatitis. J Allergy Clin Immunol 2002; 110(3): 357–365.
23. Wollenberg A., Wagner M., Günther S., Towarowski A., Tuma E., Moderer M. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002; 119(5): 1096–1102.
24. Uchida Y., Kurasawa K., Nakajima H., Nakagawa N., Tanabe E., Sueishi M. et al. Increase of dendritic cells of type 2 (DC2) by altered response to IL-4 in atopic patients. J Allergy Clin Immunol 2001; 108: 1005–1011.
25. Leung D.Y., Gao P.S., Grigoryev D.N., Rafaels N.M., Streib J.E., Howell M. Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-gamma response. J Allergy Clin Immunol 2011; 127: 965–973.e5. DOI: 10.1016/j.jaci.2011.02.010
26. Staudacher A., Hinz T., Novak N., von Bubnoff D., Bieber T. Exaggerated IDO1 expression and activity in Langerhans cells from patients with atopic dermatitis upon viral stimulation: a potential predictive biomarker for high risk of Eczema herpeticum. Allergy 2015; 70(11): 1432–1439. DOI: 10.1111/all.12699
27. Gallo R.L., Murakami M., Ohtake T., Zaiou M. Biology and clinical relevance of naturally occurring antimicrobial peptides. JAllergyClin Immunol 2002; 110: 823–831.
28. Schauber J., Gallo R.L. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol 2008; 122(2): 261–266. DOI: 10.1016/j.jaci.2008.03.027
29. Jones J.F., Howell M.D., Kisich K.O., Streib J.E., Gallo R.L., Leung D.Y.M. Deficiency of LL-37 in atopic skin may contribute to eczema vaccinatum (EV). J AllergyClin Immunol 2003; 111: 908.
30. Ong P.Y., Ohtake T., Brandt C., Strickland I., Boguniewicz M., Ganz T. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347(15): 1151–1160.
31. Howell M.D., Boguniewicz M., Pastore S., Novak N., Bieber T. Mechanism of HBD-3 deficiency in atopic dermatitis. Clin Immunol 2006; 121: 332–338. DOI: 10.1016/j. clim.2006.08.008
32. Umene K., Yoshida M., Sakaoka H. Comparison of the association with eczema herpeticum in the two predominant genotypes of herpes simplex virus type 1. J Med Virol 1996; 49(4): 329–332.
33. Yoshida M., Umene K. Close association of predominant genotype of herpes simplex virus type 1 with eczema herpeticum analyzed using restriction fragment length polymorphism of polymerase chain reaction. J Virol Methods 2003; 109: 11–16.
34. Висмонт Ф.И. Патологическая физиология. Минск: БГМУ 2016; 217–220. [Vismont F.I. Pathologic physiology. Minsk: BGMU 2016; 217–220. (in Russ)]
35. Wollenberg A.,Wetzel S., Burgdorf W.H., Haas J. Viral infections in atopic dermatitis: pathogenic aspects and clinical management. J Allergy Clin Immunol 2003; 112: 667–674.
36. Стадникова А.С., Тамразова О.Б., Чеботарева Т.А. Роль генетических детерминант и нарушений в системном и местном иммунитете в этиологии и патогенезе герпетической экземы (экземе Капоши). Детские инфекции 2016; 3: 42–45. [Stadnikova A.S., Tamrazova O.B., Chebotareva T.A. The role of genetic determinants and disorders in systemic and local immunity in the etiology and pathogenesis of Herpetic Eczema (Kaposi’s Eczema). Detskie infektsii 2016; 3: 42–45. (in Russ)]
37. Donald Y., LeungM. Why is eczema herpeticum unexpectedly rare? Antiviral Research 2013; 98: 153–157. DOI: 10.1016/j. antiviral.2013.02.010
38. Kim K., Kang J., Won Kim S., Sung M. Relationship Between the Presence of Eczema Herpeticum and the Significance of Clinical and Laboratory Tests in Korean Children With Atopic Dermatitis. Iran J Pediatr 2016; 26(4): e4683. DOI: 10.5812/ijp.4683
39. Broccardo C.J., Mahaffey S., Schwarz J., Wruck L., David G., Schlievert P.M. et al. Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and Staphylococcus aureus colonization. J Allergy Clin Immunol 2011; 127(1): 186–193. DOI: 10.1016/j.jaci.2010.10.033
40. Стадникова А.С., Тамразова О.Б., Чеботарева Т.А. Клинико-эпидемиологические особенности течения экземы Капоши у детей. Consilium Medicum (Педиатрия) 2016; 1: 64–65. [Stadnikova A.S., Tamrazova O.B., Chebotareva T.A. The Case of Herpetic Eczema in a Child with Congenital Ichthyosis and Atopic Dermatitis. Consilium Medicum (Pediatriya) 2016; 1: 64–65. (in Russ)
41. Hsu D. Y., Shinkai K., Silverberg J.I. Analysisof a Nationwide Cohort. J Invest Dermatol 2018; 138(2): 265–272. DOI: 10.1016/j.jid.2017.08.039
42. Frisch S., Siegfried E.C. The clinical spectrum and therapeutic challenge of eczema herpeticum. Pediatr Dermatol 2011; 28(1): 46–52. DOI: 10.1111/j.1525-1470.2010.01356.x
43. Beck L.A., Boguniewicz M., Hata T., Schneider L.C., Hanifin J., Gallo R. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. J Allergy Clin Immunol 2009; 124(2): 260–269. DOI: 10.1016/j.jaci.2009.05.020
44. Bin L., Kim B.E., Brauweiler A., Goleva E., Streib J., Ji Y. et al. Staphylococcus aureus alpha-toxin modulates skin host response to viral infection. J Allergy Clin Immunol 2012; 130(3): 683–691. DOI: 10.1016/j.jaci.2012.06.019
45. Broccardo C.J., Mahaffey S., Schwarz J., Wruck L., David G., Schlievert P.M. et al. Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and Staphylococcus aureus colonization. J Allergy Clin Immunol 2011; 127(1): 186–193. DOI: 10.1016/j.jaci.2010.10.033
46. Bauer A., Lange N., Matterne U., Meurer M., Braeutigam M., Diepgen T.L. Efficacy of pimecrolimus 1% cream in the long term management of atopic hand dermatitis. A double-blind RCT. J Dtsch Dermatol Ges 2012; 10(6): 426–433. DOI: 10.1111/j.1610-0387.2011.07832.x
47. Lubbe J., Pournaras C.C., Saurat J.H. Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment. Dermatol 2000; 201(3): 249–251.
48. Wheeler C.Jr., Abele D.C. Eczema herpeticum, primary and recurrent. Arch Dermatol 1966; 93: 162–173.
Review
For citations:
Tamrazova O.B., Chebotareva T.A., Stadnikova A.S., Taganov A.V. Clinical manifestations of herpes simplex virus infection in children with atopic dermatitis. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2018;63(6):15-22. (In Russ.) https://doi.org/10.21508/1027-4065-2018-63-6-15-22
Views:
2320
Email this article 